Marie-Ange Demoitié is the Vaccine Project Leader for the development of vaccines against Tuberculosis at GlaxoSmithKline (GSK) in Belgium. Since 2008, she is leading the Project Team accountable for the development of the candidate vaccine M72/AS01E in collaboration with AERAS and previously with TBVI (formerly TBVAC). She joined the R&D department of GSK Vaccines in 2001 in the field of Immunology for the development of vaccines against Tuberculosis, Malaria and HIV. Prior to joining GSK, she has worked for 7 years on molecular biology and immunology of HIV and cancer at the University of Liege and the University of Louvain in Belgium, at the University of Michigan, Ann Arbor and at The Aaron Diamond AIDS Research Center, New York, U.S.A. She received her Biochemistry Degree from the University of Liege, Belgium.
